Alphamab Oncology (HK:9966) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alphamab Oncology has received approval from China’s National Medical Products Administration to start a Phase III clinical trial for its drug JSKN003, targeting platinum-resistant recurrent ovarian cancer. This innovative treatment, part of Alphamab’s diverse portfolio of antibody-based therapies, showcases the company’s commitment to advancing cancer treatment options. Investors and stakeholders are keeping a keen eye on this development, which could significantly impact Alphamab’s market performance.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue